Feb 17 - The Horizon of Prenatal Therapies for Genetic Disorders
Availability
Registration ends on February 17, 2026
Expires on Mar 17, 2026
Online Meeting
Feb 17, 2026 2:00 PM - 3:00 PM ET
Cost
$0.00
Credit Offered
1 CME (AMA) Credit
1 CME (Other) Credit
1 P.A.C.E. Credit

 

Title: The Horizon of Prenatal Therapies for Genetic Disorders

 

Hosted by The Education and Professional Development Committee

 

Tuesday, February 17 | 2:00pm-3:00pm ET

1.0 AMA PRA Category 1 Credits™, P.A.C.E.® - Educational Credits Claim by March 17

 

Session Description: Learn about the evolving therapies available to treat fetuses affected by complicated genetic disorders. In this session, presenters will review the fetal presentation of lysosomal storage disorders (LSDs) and spinal muscular atrophy (SMA) and discuss novel therapeutic strategies including an ongoing phase 1 clinical trial of in utero enzyme replacement for LSDs and the prenatal use of an SMN2 splicing modifier to treat fetuses with SMA.

 

Agenda

  1. Fetal lysosomal storage disorders (LSDs): review of the presentation and update on the clinical trial of in utero enzyme replacement therapy
  1. In utero treatment of fetuses with spinal muscular atrophy (SMA): clinical challenges and ethical considerations of prenatal risdiplam administration
  1. Q&A

 

Target Audience: Clinical geneticists, genetic counselors, Maternal-Fetal-Medicine physicians, researchers of all levels

 

Learning Objectives

 

At the conclusion of this session, participants should be able to:

  • Recognize prenatal clinical and imaging presentations of lysosomal storage disorders (LSDs).
  • Describe the scientific rationale for the ongoing Phase 1 clinical trial of in utero enzyme replacement therapy, including the potential benefits and risks.
  • Describe the clinical, technical, and logistical challenges associated with delivering in utero therapy for fetuses with genetic disorders.
  • Evaluate the ethical considerations, safety profile, and emerging efficacy data related to prenatal risdiplam administration for the treatment of spinal muscular atrophy in utero.
no image

Moderator: Roya Mostafavi, MS, CGC
University of Washington School of Medicine

 

 

no image

Presenter: Billie Lianoglou, CGC
University of California, San Francisco

no image

Presenter: Richard Finkel, MD
St. Jude Children’s Research Hospital



Planners

Henry J. Mroczkowski, MD, PhD, FACMG (Chair)

University of TN Health Science Ctr

 

Mari Mori, MD, MS, FACMG

The Ohio State University

 

Georgianne L. Arnold, MD, FACMG

University of Pittsburgh

 

Roya M. Mostafavi, MGC

University of Washington School of Medicine

 

Catherine A. Ziats, MD, FACMG

Cook Children's

 

Damara Ortiz, MD, FACMG

Children's Hospital of Pittsburgh of UPMC

 

Daniel Schecter, MD, MS

Mount Sinai School of Medicine

 

Staff

Jane Radford, MHA, CHCP

Director of Education

 

Claudia Barnett

Senior Program Coordinator

Accredited Continuing Education Information:

AMA PRA Category 1 CreditTM, ASCLS P.A.C.E.®

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted.

 

Learner Data Consent

ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.

 

Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.

 

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

 

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

All of the relevant financial relationships listed for these individuals have been mitigated.

Name

Role

Relationship/Company

Billie Lianoglou, CGC

CE Presenter

Pending

Richard Finkel, MD

 

CE Presenter

Pending


Mari Mori, MD, MS, FACMG

 


Planner

Research Grant(ended 11/2024): HemoShear Therapeutics

Research Grant (ended 7/2024): Sanofi and Genzyme US Companies

Henry J. Mroczkowski, MD, PhD, FACMG

Planner, 

No Relevant Financial Relationships

Georgianne L. Arnold, MD, FACMG

Planner

No Relevant Financial Relationships

Roya M. Mostafavi, MGC


Planner, Moderator

No Relevant Financial Relationships


Catherine A. Ziats, MD, FACMG

 

Planner

No Relevant Financial Relationships

Damara Ortiz, MD, FACMG

 

Planner

Research Grant: Amicus Therapeutics, Freeline Therapeutics,
GC Biopharma, Sanofi and Genzyme US Companies, Uniqure

Daniel Schecter, MD, MS

 

Planner

No Relevant Financial Relationships

Jane Radford, MHA, CHCP

Staff

No Relevant Financial Relationships

Claudia Barnett

Staff

No Relevant Financial Relationships

 

 

Disclaimer

ACMG educational programs are designed primarily as an educational tool for healthcare professionals who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and or exclusive of other procedures and that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare professional should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net

 

© American College of Medical Genetics and Genomics. All rights reserved.

Powered By